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CONCLUSIONS: Treatment satisfaction data has been used in a limited way to 
support EMEA drug approvals but the value of this data in support of product appro-
vals has not been fully achieved. It is recommended that treatment satisfaction data 
be collected using carefully developed and validated patient-reported questionnaires, 
with greater attention to instrument description and data reporting in approval 
documents.
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OBJECTIVES: During the PRO linguistic validation process, harmonisation is vital; 
it ensures conceptual equivalence of the translations, allowing trial data to be com-
pared across cultures. The 2005 ISPOR Taskforce Report outlined two methods for 
achieving harmonisation: a formal meeting with translators from each target language 
and the instrument developer, or an ongoing process whereby solutions to common 
problems are conveyed to all translators through rigorous quality control. This study 
aims to evaluate both methods to ascertain the most efﬁcient, thorough and cost-
effective for sponsors. METHODS: Eight projects were reviewed. Four included a 
harmonisation meeting via teleconference with translators from each target language 
and the instrument developer. During the meeting, the developer and project manager 
discussed each item and ensured that it had been correctly conveyed in all language 
versions. Four other projects were harmonised through a detailed concept elaboration, 
created in collaboration with the developer. This document was continually updated; 
wherever problems arose, the resolution was incorporated. The document was con-
sulted by translators at each step of the process. Each method was evaluated to 
determine the optimal process. RESULTS: Both methods achieved harmonised transla-
tions. The ﬁrst added at least a week to the timelines, with the cost to the sponsor 
also signiﬁcantly higher, though translators felt it useful to speak with the developer. 
Several translators noted the value of ongoing harmonisation as per the second meth-
odology; with the ﬁrst method, the meeting occurred after back translation, and 
therefore changes may occur later in the validation process that are not subject to 
formal harmonisation. In contrast the second methodology provides support through-
out, and includes developer input. CONCLUSIONS: The harmonisation procedure is 
key to the translation process, and both methodologies achieved harmonised transla-
tions. However, the less formal approach shortened the timeline and reduced the cost 
for the sponsor, without sacriﬁcing harmonisation.
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INITIAL EXPERIENCE WITH THE PROMIS MEASUREMENT SYSTEM IN 
CLINICAL POPULATIONS
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OBJECTIVES: The PROMIS system has undergone extensive validity testing in com-
munity populations, but has been much less studied in clinic patient populations. We 
studied the time required for administration of speciﬁc PROMIS CAT and short form 
measures and the experience of patients using the system as expressed in responses to 
evaluation questions. METHODS: A convenience sample of patients receiving care 
for either neurological or surgical conditions, and caregivers of patients being treated 
for mild dementia (total N = 66) were recruited from Henry Ford Hospital outpatient 
clinics. They were invited to complete a set of PROMIS CAT measures and short form 
surveys, and then asked to respond to a set of questions about their experience with 
the PROMIS system. RESULTS: No respondents failed to complete a measurement 
section. Patient and caregiver ratings of the PROMIS system were very positive. 94% 
reported liking using the system. 98% reported that it was either “easy” or “very 
easy” to use. 92% found the questions easy to understand, and 93% felt that they 
could choose answers that reﬂected their feelings on most or all questions. 71% 
reported that the number of questions asked was “just right”, and 68% reported that 
they would rather answer questions on a computer than on a paper form. The 
responses of individual clinical subgroups and of caregivers were quite similar to the 
overall pattern of responses. On average, each PROMIS CAT module took respon-
dents approximately 1.5 minutes to complete. CONCLUSIONS: Clinic patients, 
including those being treated for conditions involving possible cognitive deﬁcits, were 
able to complete all PROMIS CAT or short form measures presented, and reported 
high levels of satisfaction with, and ease of, use of the system as a way to respond to 
questions on health status.
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BACKGROUND: FDA’s 2007 reauthorization legislation requires the agency to 
evaluate strategies for comparing the beneﬁts and risks of pharmaceuticals. The 
Pharmaceutical Research and Manufacturers of America’s Beneﬁt-Risk Action Team 
(PhRMA BRAT) has developed a comprehensive Framework of processes and tools 
for organizing and interpreting evidence to assist in beneﬁt-risk decisions. While not 
a required component of the Framework, patient preference weights are one of several 
possible options for comparing beneﬁts and risks within it. OBJECTIVES: Obtain 
valid patient preference weights to support beneﬁt-risk analysis of anti-hypercholes-
terolemia treatments. METHODS: US residents aged 18 years or older with a self-
reported physician diagnosis of hypercholesterolemia completed a choice-format 
conjoint survey. Patients evaluated a series of choice tasks involving two hypothetical 
statins. Medication attributes corresponded to probabilistic endpoints speciﬁed in the 
BRAT Framework, including three cardiovascular outcomes, three hepatotoxicity 
outcomes, and three nephrotoxicity outcomes. Risk levels for various outcomes ranged 
from zero to 10%. RESULTS: Six hundred subjects enrolled in a nationally representa-
tive web panel completed the survey. Between 80% and 95% of subjects passed each 
of 3 internal validity tests. Estimated importance weights were correctly ordered over 
endpoint severity and over risk levels for each endpoint. Patients were willing to accept 
signiﬁcant treatment risks in exchange for sufﬁciently large treatment beneﬁts. For 
example, the preference weight for a medication that would reduce the risk of heart 
attack or stroke from 4% to zero but increase risk of kidney failure from zero to 0.5% 
is about 1.5 times larger than a medication that would reduce the risk of heart attack 
or stroke by from 4% to 2% with no kidney-failure risk. CONCLUSIONS: Patients 
had well-deﬁned preferences for clinically relevant outcomes of statin treatments. 
Using such preference weights to compare beneﬁts and risks offers a possible solution 
for evaluating therapeutic beneﬁts and risks that are quantiﬁed using dissimilar 
metrics.
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OBJECTIVES: The PROMIS system has undergone extensive validity testing in com-
munity populations, but has been much less studied in clinic patient populations. We 
examined the patterns of correlation between the PROMIS Global Health Short Form 
measure and various scale scores on the SF-36. METHODS: A series of patients (total 
N = 13) being seen for pre-surgical consultation were recruited from Henry Ford 
Hospital surgery outpatient clinic. They were invited to complete a set of PROMIS 
CAT measures and the Global Health short form, and were also asked to complete 
the SF-36 survey. SF-36 dimensions were scored on a 0–100 scale; Spearman correla-
tion coefﬁcients were calculated as the primary measure of agreement. RESULTS: All 
of the correlations between PROMIS Global Health Score and SF-36 domain scores 
were in the expected directions, but none reached conventional levels of statistical 
signiﬁcance except the correlation between PROMIS Global Health and SF-36 General 
Health (r = .55, p = 0.054). Scores for essentially all the individual items within the 
PROMIS Global Health measure, though, were signiﬁcantly correlated with both 
SF-36 General Health and SF-36 Bodily Pain. Other individual items in the PROMIS 
measure correlated signiﬁcantly with one or more SF-36 domain scores. CONCLU-
SIONS: In this preliminary study of PROMIS measures in surgery patients, a pattern 
of general agreement between PROMIS Global Health and SF-36 domain scores was 
observed. The modest levels of correlation, though, and the unexpected ﬁnding of 
higher correlations between the SF-36 scores and individual PROMIS scale items than 
between SF-36 scores and the total PROMIS scale score suggest the need for further 
exploration in a larger sample of clinic patients.
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OBJECTIVES: Health Technology Assessment (HTA) provides quantitative estimates 
of the efﬁcacy and safety of new drug entities as well as cost-effectiveness to provide 
guidance for reimbursement and market access decisions. There is a growing recogni-
tion that when balancing costs and effectiveness, it is important to include inputs 
reﬂecting the patients’ voice. METHODS: A review of HTA regulatory guidance 
documents and supporting literature was conducted for the US, Britain, Canada, 
Germany, and Australia. The role of the patient voice in relation to product appraisal 
was compared across these differing countries. RESULTS: Examples of Patient 
Reported Outcomes (PROs) that have been evaluated within the quantitative HTA 
include impact on quality of life, utility, and functional status. Beyond PRO, the 
patient voice has been captured through advisory boards, patient advocacy groups 
and other direct patient input mechanisms. Of the ﬁve countries, Britain (NICE) has 
the most experience with both patient and public involvement in HTA via direct 
consultation, citizen groups and partners groups, supported by formal policy. The 
patient voice directly in policy decisions is emerging in both Canada and Australia as 
guidance documents and processes are updated. In Germany, the patient voice is 
sought via consultation with patient groups though their focus is on efﬁcacy rather 
than issues of HRQL. In the US, comparative effectiveness research provides a vehicle 
for the patient voice with patient and consumer participation in priority setting and 
information dissemination as supported by proposed legislation. CONCLUSIONS: 
The role of the patient voice in HTA extends beyond that of PRO measures and utility 
analysis. Direct input from patients and consumer advocacy groups are being included 
in policy decisions in all the countries whose guidelines were reviewed for this study. 
This can be seen as an essential step in applying the results of the quantitative HTA.
